Nuclear Medicine, Molecular imaging, Oncology, Urinary Tract / Bladder, PET-CT, SPECT-CT, PET, Radionuclide therapy, Treatment effects, Safety, Radiotherapy techniques, Metastases, Quality assurance, Not applicable
M. Vyas; Auckland/NZ
Findings and procedure details
Explored database i.e. PubMed, EBSCO, CINAHL, Medline and Google Scholar. Considered peer-reviewed journal articles written in English and published between 2005-2019. The search strategy and selection criteria were based on the peer-reviewed preferred reporting items for systematic reviews and meta-analysis (PRISMA). The search term used for Literature search including “ Lu-177-PSMA”, “mCRPC treatment AND third-line treatment”, “Lu-177-PSMA AND Quality of life”
Reviewed literature found that Lu-177-PSMA based shows comparable results of the existing third-line treatment for mCRPC (see Image 1 and 2). Radionuclide Lu177-PSMA based treatment not only shows comparable results of the available systemic therapies (i.e. >50% reduction in PSA value from baseline, extension in the overall survival) but also have a specific character of hitting the target or bad cells precisely while keeping bad cells intact (Ahmadzadehfar, Essler, Schafers, & Rahbar, 2016; Rahbar, Afshar-Oromieh, Jadvar, & Ahmadzadehfar, 2018)( See images 3).